Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced acceptance and presentation of six posters featuring Nyxol® and APX3330 at the American Academy of Optometry (AAOPT) 2022 Annual Meeting being held October 26-29, 2022 in San Diego, CA.
| AAOPT 2022: San Diego Convention Center | |
| Title: | Safety and Tolerability of Phentolamine Ophthalmic Solution for Reversal of Mydriasis in Two MIRA Phase 3 Trials |
| Poster #: | 260, Exhibit Hall H |
| Date/Time: | Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT |
| Presenter: | Justin Schweitzer, OD |
| Title: | Masked Safety of Oral Drug Candidate APX3330 for the Treatment of Diabetic Retinopathy in an Ongoing ZETA-1 Phase 2b Clinical Trial |
| Poster #: | 200, Exhibit Hall H |
| Date/Time: | Thursday, October 27, 2022, 4:30 PM – 6:30 PM PT |
| Presenter: | Doug Devries, OD |
| Title: | Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal MIRA Phase 3 Trials |
| Poster #: | 188, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Leslie O'Dell, OD |
| Title: | MIRA-4, Clinical Trial Evaluating the Safety and Efficacy of Phentolamine Ophthalmic Solution for Reversal of Pharmacologically Induced Mydriasis in Pediatric Subjects Aged 3-11 Years |
| Poster #: | 187, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Shane Foster, OD |
| Title: | Phentolamine Alone and in Combination with Low Dose Pilocarpine Improves Near Vision in Presbyopic Subjects in the VEGA-1 Phase 2 Trial |
| Poster #: | 186, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Mitch Ibach, OD |
| Title: | LYNX-1: A Pivotal Phase 3 Randomized Placebo-Controlled Trial of Phentolamine Ophthalmic Solution in Subjects with Dim Light Vision Disturbance |
| Poster #: | 185, Exhibit Hall H |
| Date/Time: | Friday, October 28, 2022, 1:00 PM – 3:00 PM PT |
| Presenter: | Shane Kannarr, OD |
About Ocuphire Pharma
Ocuphire is a publicly traded (Nasdaq: OCUP), clinical-stage, ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of refractive and retinal eye disorders. For more information about Ocuphire’s clinical trials, visit https://www.ocuphire.com/clinical-trials.
Ocuphire Contacts
Mina Sooch, President & CEO
Ocuphire Pharma, Inc.
ir@ocuphire.com
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Bret Shapiro
Core IR
brets@coreir.com
